Retinoid and Rexinoid Signaling pp 171-180 | Cite as
Evaluating the Role of RARβ Signaling on Cellular Metabolism in Melanoma Using the Seahorse XF Analyzer
- 2 Citations
- 544 Downloads
Abstract
Dysregulation of retinoic acid signaling is implicated in several human cancer types, including melanoma where the gene encoding retinoic acid receptor beta (RARβ) is frequently silenced by promoter hypermethylation. In this chapter, we describe some of the experimental procedures that we have used to characterize the role of RARβ signaling on the regulation of cellular metabolism in melanoma. Central to these studies is the use of the Seahorse XF Analyzer, which allows real-time assessment of the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in cultured cells as readouts for oxidative phosphorylation and glycolysis, respectively. The levels of RARβ signaling can be modulated using RARβ agonists (e.g., all-trans retinoic acid) and antagonists (e.g., LE135). The bioenergetic profiles of melanoma cells in response to RARβ modulators and other metabolic modifiers can be the basis for defining new therapeutic strategies.
Key words
Retinoic acid receptor β Seahorse XF Analyzer Cancer metabolism Melanoma Mitochondrial function Glycolytic activity Warburg effect Oxygen consumption rate Extracellular acidification rate Metabolic profileReferences
- 1.Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8(6):519–530CrossRefGoogle Scholar
- 2.Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033CrossRefGoogle Scholar
- 3.Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRefGoogle Scholar
- 4.Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10(9):671–684CrossRefGoogle Scholar
- 5.Amoedo ND, Obre E, Rossignol R (2017) Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy. Biochim Biophys Acta 1858(8):674–685CrossRefGoogle Scholar
- 6.Ratnikov BI, Scott DA, Osterman AL, Smith JW, Ronai ZA (2017) Metabolic rewiring in melanoma. Oncogene 36(2):147–157CrossRefGoogle Scholar
- 7.Abildgaard C, Guldberg P (2015) Molecular drivers of cellular metabolic reprogramming in melanoma. Trends Mol Med 21(3):164–171CrossRefGoogle Scholar
- 8.Dahl C, Christensen C, Jönsson G, Lorentzen A, Skjødt ML, Borg A, Pawelec G, Guldberg P (2013) Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14ARF and RARbeta signaling. Mol Cancer Res 11(10):1166–1178CrossRefGoogle Scholar
- 9.Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B (2004) Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23(22):4014–4022CrossRefGoogle Scholar
- 10.Abildgaard C, Dahl C, Abdul-Al A, Christensen A, Guldberg P (2017) Inhibition of retinoic acid receptor ß signaling confers glycolytic dependence and sensitization to dichloroacetate in melanoma cells. Oncotarget 8(48):84210–84223CrossRefGoogle Scholar
- 11.Li Y, Hashimoto Y, Agadir A, Kagechika H, Zhang X (1999) Identification of a novel class of retinoic acid receptor beta-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. J Biol Chem 274(22):15360–15366CrossRefGoogle Scholar